Figure 7
T and B immunophenotype predominance in lymphoproliferative disease ( 23 lymphomas; 3 lymphocytic leukaemias). (%) CD21+ and (%) CD3+ percentages obtained by the Guava analyzer for the lymphoma / leukaemia samples included in this study. The percentages are shown separately for the T-cell, the B-cell and the non-T non-B cell tumors. There is clear separation between the cell populations allowing the identification of the predominant immunophenotype in most cases.